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This article reviews the contemporary data concerning atherosclerosis and protecting properties of
garlic. Recent advances in basic science have established a fundamental role for inflammation in
mediating all stages of this disease from initiation through progression and, ultimately, the thrombotic
complications of atherosclerosis. These new findings provide important links between risk factors
and the mechanisms of atherogenesis and garlic properties. Numerous in vitro studies have confirmed
the ability of garlic to reduce the parameters of the risk of atherosclerosis: total cholesterol, LDL,
triglycerides, oxidized LDL. Bioactive compounds and antioxidant potentials in fresh, cooked, boiled
and commercial garlic from different regions are presented, using b-carotene, 1,1-diphenyl-2-picryl-
hydrazyl (DPPH), nitric oxide (NO), 2,29-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) diammo-
nium salt (ABTS) with K2S2O8 or MnO2, ferric-reducing/antioxidant power (FRAP), cupric reducing
antioxidant capacity (CUPRAC) and others assays for antioxidant status. In vivo studies were
reviewed on with garlic and cholesterol supplemented diets. The positive influences of garlic on
plasma lipids, proteins, antioxidant activity, and some indices of blood coagulation are dose depend-
ent. Garlic could be a valuable component of atherosclerosis-preventing diets only in optimal doses.
Many recently published reports show that garlic possesses plasma lipid-lowering and plasma antico-
agulant and antioxidant properties and improves impaired endothelial function.
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1 Diseasedefinition
Atherosclerosis, the principal cause of heart attack, stroke
and gangrene of the extremities, is responsible for 50% of
all mortality in the USA, Europe and Japan. The lesions
result from an excessive, inflammatory-fibroproliferative
response to various forms of insult to the endothelium and
smooth muscle of the artery wall. A large number of growth
factors, cytokines and vasoregulatory molecules participate
inthis process [1,2].
Nowadays most of the scientists agree that atherosclero-
sis is a complex process, characterized by an inflammatory,
fibro-fatty, proliferative response to damage of the artery
wall involving smooth muscle cells, monocyte-derived
macrophages, T-lymphocyte and platelets and that hyperli-
pidemia constitutes a major etiopathological factor for this
disease.Itwasalongwaybeforemostofthescientistsagree
tothis definition.
As reported by Kritchevsky [3], the first purely nutri-
tional investigation into experimental atherosclerosis was
carried out by Ignatowski in 1908. Believing that a toxic
metabolite of animal protein led to atherosclerosis, he fed
meat toadult rabbits and milk and eggyolktoweanling rab-
bits and caused atherosclerosis. The discovery in 1912 that
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dietary cholesterol per se was atherogenic turned attention
to fat and cholesterol, eclipsing work on dietary protein.
Since this times many thousand experiments, clinical and
epidemiological investigations demonstrated the central
roleofdietarycholesterol indevelopmentofatherosclerotic
changes in the arteries of animals and humans alike.
Intensive clinical and epidemiological investigations
have shown that not only dietary cholesterol takes part in
the atherosclerosis process. More than 200 risk factors for
atherosclerosis have been identified [4]. The three most
important are (i) abnormal lipids including familial hyper-
cholesterolemia [5], (ii) cigarette smoking and (iii) high
blood pressure. In addition, many other factors including
homocysteine, haemostatic factors such as fibrinogen, C-
reactive protein and other are known as factors increasing
the risk of atherosclerosis development.
It was demonstrated that among plasma lipids low-den-
sity lipoprotein cholesterol (LDL-C) and low HDL-C level
are the most atherogenic [6]. However, only oxidized LDL-
C particles are able to penetrate arterial walls and cause
their occlusion [7, 8].
Atherosclerosis begins in childhood as deposits of cho-
lesterol and its esters, referred to as fatty streaks, in the
intima of large muscular arteries. In some persons and at
certain arterial sites, more lipids accumulate and covered
by a fibromuscular cap form a fibrous plaque [9]. The focal
arterial lesion-prone sites play an important role [6]. Key
initial participants in these sites include the focal intimal
influx and accumulation of LDL-C and a preferential
recruitment of blood monocytes. Both are further enhanced
inthepresenceof hyperlipidemia,whenthequantityof inti-
mal LDL-C and the oxidative potential of the intima exceed
the capacity of macrophages to remove, via the non-down-
regulating scavenger receptor, cytotoxic anionic (Ox-LDL)
macromolecules. Foam cells, pathognomonic of the fatty
streak, form during the receptor-mediated uptake of Ox-
LDL by the macrophages. Interstitial free radicals and the
excess of Ox-LDL particles injure and kill cells, including
the foam cells, with the formation of the necrotic extracel-
lular lipid core, a key transitional step in lesion progression.
Monocyte-macrophage recruitment to the intima is likely to
be regulated not only by a multiplicity of endothelial adhe-
sive cytokines, integrins, and selectins, but also by the
monocyte-specific chemoattractant, MCP-1, constitutively
synthesized and secreted by intimal smooth muscle and
endothelial cells. Platelets and mural thrombosis directly
contribute to subsequent plaque growth, particularly after
plaque rupture or fissure and disruption of the thrombore-
sistant endothelial cells [6].
In the atherosclerotic process macrophages are very
important for intracellular lipid accumulation and foam cell
formation [10]. Monocytes respond to chemotactic factors,
cytokines,andmacrophagegrowthfactorsproducedbyvas-
cular endothelial cells, smooth muscle cells, and infiltrated
cells, by migrating from peripheral blood into the arterial
intima and differentiating into macrophages in atheroscler-
otic lesions. Although various chemotactic factors are
known to induce monocyte migration, monocyte chemoat-
tractant protein-1 is the most important and powerful
inducer of migration into atherosclerotic lesions. Macro-
phage colony-stimulating factor is crucial for monocyte/
macrophage differentiation and proliferation, and for the
survival of macrophages in these lesions. Macrophages also
play multifaceted roles in inducing plaque rupture, blood
coagulation, and fibrinolysis via the production of various
enzymes, activators, inhibitors, and bioactive mediators.
During the development of atherosclerosis, macrophages
interact with vascular endothelial cells, medial smooth
muscle cells, and infiltrated inflammatory cells, particu-
larly Tcells and dendritic cells [10].
An increasingbodyofevidencedeterminedatherosclero-
sis as an inflammatory disease [11–15]. The above-cited
investigationsled Libbyet al.[16] to aconclusionthatathe-
rosclerosis, formerly considered a bland lipid storage dis-
ease, actually involves an ongoing inflammatory response.
Recent advances in basic science have established a funda-
mental role for inflammation in mediating all stages of this
disease from initiation through progression and, ultimately,
the thrombotic complications of atherosclerosis. These new
findings provide important links between risk factors and
the mechanisms of atherogenesis.
Smoking contributes significantly to atherosclerosis
morbidity and mortality. It affects all phases of atheroscle-
rosis from endothelial dysfunction to acute clinical events,
the latter being largely thrombotic. Both active and passive
(environmental) smoke exposure predispose to cardiovas-
cular events [17]. Whether there is a distinct direct dose-
dependent correlation between smoke exposure and risk is
debatable, as some recent experimental clinical studies
have shown a nonlinear relation to cigarette smoke expo-
sure [17]. The exact toxic components of cigarette smoke
(CS) and the mechanisms involved in CS-related cardiovas-
cular dysfunction are largely unknown, but CS increases
inflammation, thrombosis, and oxidationof LDL-C. Recent
experimental and clinical data support the hypothesis that
cigarette smoke exposure increases oxidative stress as a
potential mechanism for initiating cardiovascular dysfunc-
tion[17].Theinfluenceof CS ismore substantial inpersons
suffering from diseases, which are connected to atheroscle-
rosis [18].This factwas supported by the below cited trial.
The aim of this trial was to examine the impact of active
smoking and exposure to environmental tobacco smoke
(ETS) on the progression of atherosclerosis. A total of
10 914 participants from the Atherosclerosis Risk in Com-
munities (ARIC) study were enrolled between 1987 and
1989. The changes in atherosclerosis were examined from
baseline to the 3-year follow-up as indexed by intimal-
medial thickness of the carotid artery, assessed by ultra-
sound, and adjusted for demographic characteristics, cardi-
ovascular risk factors, and lifestyle variables. The authors
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found that exposure to cigarette smoke was associated with
progression of atherosclerosis. Relative to never-smokers
and after adjustment for demographic characteristics, cardi-
ovascular risk factors, and lifestyle variables, current ciga-
rette smoking was associated with a 50% increase in the
progression of atherosclerosis. Smoking is of particular
concernfor patientswith diabetes and hypertension [19].
Atherosclerotic changes were reported also in young
smokers [20]. A multicenter cooperative study, Pathobio-
logical Determinants of Atherosclerosis in Youth (PDAY),
was organized to study atherosclerosis in trauma victims
15–34 years of age. It was demonstrated that smoking is
strongly associated with the prevalence and extent of
grossly visible raised lesions in the abdominal aorta. Coro-
nary arteries from 50 smokers and 50 non-smokers were
classified microscopically using a system developed by the
American Heart Association in order to determine the stage
at which smoking affects atherosclerosis. Smokers had over
twice as many advanced lesions, as non-smokers (32 vs.
14%).
The passive smoking is a risk factor for atherosclerosis.
The passive smoking affect the antioxidant defense of
human serum, the extent of lipid peroxidation, and the
accumulation of LDL-C in cultured human macrophages,
the precursors of foam cells in atherosclerotic lesions [21].
The above-cited data provide the pathophysiological back-
ground for the recent epidemiological evidence about the
increased atherosclerosis risk among passivesmokers.
The effects of even brief passive smoking are often
nearly as large (averaging 80 to 90%) as chronic active
smoking [22].
The importance of the cessation of smoking was under-
lined by Bolego et al. [23]. They found that the incidence of
coronary artery and cerebrovascular diseases in ex-smokers
consistently decreases after cessation, further underlying
the relevance of smoking as a risk factor for these patholog-
ical conditions.
There is much evidence that hypertension is one of the
major risk factors for atherosclerosis [24, 25]: elevated lev-
els of blood pressure correlate with elevated risk of athero-
sclerotic complications, although the mechanisms have not
been well elucidated. As the cellular and molecular mecha-
nisms of the pathogenesis of atherosclerosis and the effects
of hypertension are being more clearly defined, it becomes
apparentthatthetwoprocesses havecertaincommonmech-
anisms. There is increasing evidence that atherosclerosis
should be viewed fundamentally as an inflammatory dis-
ease and the endothelium is a likely central focus for the
effectof both diseases [26, 27].
In spite of the fact that until now the etiopathogenesis of
hypertension is not defined, this illness can be well treated
not only by pharmacological means. Weight loss, alcohol
reduction,sodiumrestrictionandespeciallyincreased phys-
ical activity could be helpful in treatment of this disease.
Therefore, in a population-based prospective cohort study
among men with hypertension, vigorous physical activity
was associated with markedly reduced rates of cardiovascu-
lar mortality: 6.3 versus 21.0 deaths per 1000 person-years
[28]. Reduction of blood pressure greatly reduces the risk
of atherosclerotic complications. Decrease of the diastolic
blood pressure of 5 to 6 mm Hg reduces the risk of stroke
by 40% and the risk of coronary artery disease by 14% [29].
In addition, treatment of systolic blood pressure mostly in
the elderly could beeffective[30].
The study of lipid metabolism has dominated research
into atherosclerosis etiology for decades, although now it is
widelyrecognized thatalargenumber of peoplewithsymp-
tomatic atherosclerosis have no detectable evidence of
abnormal lipid metabolism [31]. Careful review of epide-
miological studies indicates that the classic risk factors, as
hypercholesterolemia, cigarette smoking, and hyperten-
sion, account for the majority but not the entirety of the eti-
ology and pathogenesis of the clinical complications of
atherosclerosis [32]. Evidence has accumulated that factors
other than conventional risk factors may contribute to the
development of atherosclerosis [33]. These newer risk fac-
tors for atherosclerosis include homocysteine, fibrinogen,
impaired fibrinolysis, increased platelet reactivity, hyper-
coagulability, small dense low-density lipoprotein choles-
terol, inflammatory-infectious markers and many other
[33–36].
2 Prevalence
At the beginning of a new millenniumatherosclerotic cardi-
ovascular disease remains the leading cause of both death
and disability in North America [37]. As far as in 1993 it
has been predicted that one in three Americans would even-
tually die of cardiovascular disease [38]. In following years
due to aggressive preventive measures the death rate from
atherosclerosis had constantly declined and the largest
decline from the previous year was in 1998 – by 9.5% [39].
However, even now, atherosclerosis is the single biggest
cause of death in US and Western Europe [37]. In 1999
more than 12 million people in the United States were esti-
mated to suffer from coronary atherosclerosis and approxi-
mately 960000 died from this disease [40]. The economic
costs associated with this disease are estimated to be $ 112
billion [41].Theabove-mentioned explainswhythepreven-
tionof atherosclerosis is more thanimportant.
3 Treatment
3.1 Medication
As was mentioned, atherosclerosis is not a bland lipid stor-
age disease and actually involves an ongoing inflammatory
response [17]. It did not contradict the claims that plasma
lipids are playing a central role in progression and regres-
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sionof atherosclerosis. Therefore,the major roleinmedica-
tion of atherosclerosis is plying hypolipidemic agents. Dur-
ing last 40 years many lipid-decreasing drugs were used. At
present, the leading agents are statins (lovastatin; pravasta-
tin; simvastatin) [42–44]. The below-cited investigations
confirmthese claims.
Inarandomized,double-blind,placebo-controlled,multi-
center coronary angiographic trial, 270 patients 37 to
67 years old, with total cholesterol ranging from 190 to
295 mg/dL and angiographically defined coronary artery
disease participated. They received a cholesterol-lowering
diet and either lovastatin, 80 mg/day, or placebo. As results
of such treatment lovastatin lowered total cholesterol level
by 32%, LDL-C by 38%, and the apolipoprotein B by 26%
and raised the high-density lipoprotein cholesterol by 8.5%
(p a 0.001). According to angiographic control, for lesions
50% or greater, average percent diameter stenosis increased
0.9% in placebo recipients and decreased 4.1% in lovastatin
recipients (p= 0.005)[42].
In the next investigation, 447 subjects with serum LDL-
C levels A or = 155 mg/dL (A or = 4.0 mmol/L) and total
cholesterol (TC) levels a290 mg/dL (a7.5 mmol/L) were
randomly assigned to receive either pravastatin 40 mg/day
or placebo for 3 years. Atherosclerosis progression was
assessed with B-mode ultrasonography. The given treat-
ment reduced the rate of progression by 45% (95% confi-
dence interval [CI]: 16–69%, p = 0.005) in carotid arteries
and by 66% (95% CI: 30–90%, p = 0.002) in the common
carotid arteries. Subjects who received pravastatin had a
higher antioxidative capacity of LDL-C, a longer oxidation
lag of very low-density lipoprotein (VLDL), and a reduced
oxidation rateof LDL-C and VLDL invitro[43].
Eighteen asymptomatic hypercholesterolemic patients
with documented aortic and/or carotid atherosclerotic pla-
ques were selected for the next study. Thirty-five aortic and
25 carotid artery plaques were detected. Serial black-blood
magnetic resonance imaging (MRI) of the aorta and carotid
artery of the patients was performed at baseline and 6 and
12 months after lipid-lowering therapy with simvastatin.
Simvastatin induced a significant (p a 0.01) reduction in
TC and LDL-C levels at 6 weeks that was maintained there-
after. After 12 months of treatment, significant reductions
in vessel wall thickness and vessel wall area were observed
inbothaortic and carotid arteries (p a 0.001)[44].
All three cited studies proved that decrease in the plasma
lipid levels leads to reduced rate of atherosclerosis progres-
sion.
Theassessment ofthe results ofmeasures ofprimary pre-
vention is very important: it helps to decide if the present
treatment is effective.
Primary prevention of coronary heart disease is most
appropriate for patients at relatively high risk as shown by
Pletcher et al. [45]. These authors investigated if measure-
ment of coronary artery calcium could be proposed as a
way to improve risk assessment and found that the coronary
artery calcium score is an independent predictor of coro-
nary heart disease events. Other authors also examined
associations between cardiovascular risk factors and coro-
nary calcification byelectron-beam tomography inan unse-
lected population of older subjects (Oei et al. [46]). They
found that cardiovascular risk factors are associated with
coronary calcification.
3.2 Preventive measures
The cessation of smoking is very important: the incidence
of coronary artery and cerebrovascular diseases in ex-
smokers consistently decreases after cessation, underlying
the relevance of smoking as a risk factor for these patholog-
ical conditions [24]. In addition, reduction of blood pres-
sure greatly reduces the risk of atherosclerotic complica-
tions: as was mentioned, decrease of the diastolic blood
pressure of 5 to 6 mm Hg reduces the risk of stroke by 40%
and the risk of coronaryarterydisease by14%[29].
Therefore, in the prevention of atherosclerosis and its
complications the leading measures are decrease of the
plasma lipid levels, cessation of smoking and reduction of
bloodpressure.
An important role in the atherosclerosis prevention is
played by proper diets. These diets have to contain a lot of
vegetables and fruits and limited quantities of fats [47].
Among these diets the most effective is so-called Mediter-
ranean diet, which contains inter alia oils, vegetables and
fruits [48, 49]. Greater adherence to the traditional Mediter-
ranean diet isassociated with a significant reduction intotal
mortality [50, 51].
One of the regularly used vegetable in this diet is garlic
(Allium sativum L.).
4 Garlic
4.1 History
Garlic was used already at the beginning of the history: it
was found in Egyptian pyramids and ancient Greek temples
[52]. Some of the earliest references to this medicinal and
culinary plant are found on Sumerian clay tablets dating
from 2600–2100 BC [53]. Garlic was an important medi-
cine to the ancient Egyptians especially for the working
class involved in heavy labor and is listed in the medical
text Codex Ebers (ca. 1550 BC) [53] Ancient medical texts
from Egypt, Greece, Rome, China and India each pre-
scribed medical applications for garlic [54]. There is evi-
dence that during the earliest Olympics in Greece, garlic
was fed to the athletes as perhaps one of the earliest“per-
formance enhancing” agents [54, 55]. The leading Indian
ancient medical text, Charaka-Samhita recommends garlic
for the treatment of heart disease and arthritis. In another
ancient Indian medical textbook Bower Manuscript, garlic
is recommended for fatigue, parasitic disease, digestivedis-
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order and leprosy [53]. In addition, Hippocrates, the well-
known physician, has used garlic for treatment of some dis-
eases. It is of interest that cultures, which developed with-
out contact with one another came to similar conclusions
about the efficacy of garlic [52]. With the onset of Renais-
sance, increasing attention was paid in Europe to the medi-
cal use of garlic, which continues tothe present times.
4.2 Bioactive compounds ofgarlic and the used
garlic preparations
It has been found that the majority of raw garlic is water
(65%), and the bulk of the dry weight is composed of fruc-
tose-containing carbohydrates, followed by sulfur com-
pounds and protein [54]. Its organoleptic properties are due
to sulfuric compounds that are synthesized from gamma-
glutamyl-cysteine. As a result of cutting or crushing garlic,
the enzyme allinase decomposes alliin to produce allicin,
which is responsible for the characteristic flavor [55]. Alli-
cin(diallythiosulfinate),themostactivesubstanceofgarlic,
has been shown to possess a variety of biological activities
[56]. In addition, other investigators demonstrated that alli-
cin is the main bioactive component of freshly crushed gar-
lic cloves[57].
Progress in establishing systemic pharmacological
effects for fresh, crushed garlic in humans has been hin-
dered by (i) the inability to measure allicin bioavailability,
(ii) lack of direct evidence that allicin has significant sys-
temic activity at doses of garlic normally consumed, and
(iii) lackof a model foranacute effect[58].
The authors have addressed these problems by quantify-
ing the increases in breath acetone and breath allyl methyl
sulfide (AMS). The area under the 48-h curve was meas-
ured in humans after consumption of standardized garlic
preparations, allicin, and allicin-derived compounds, at the
equivalent of 7 g of crushed garlic. Lawson and Wang [58]
have shown that the allyl thiosulfinates (mainly allicin) are
solely responsible for breath AMS and increased breath
acetone. Diallyl trisulfide, diallyl disulfide, ajoene, and S-
allylmercaptocysteine, at isomolar dithioallyl, showed the
same quantitative effects as allicin. Consumption of AMS
at isomolar allyl also gave the same effects as allicin, indi-
cating that AMS is the main metabolite of allicin and is an
active metabolite. Lawson and Wang [58] concluded that
allicin and allicin-derived compounds are rapidly metabo-
lized to AMS, a compound that stimulates the production of
acetone and which can be used to measure the bioavailabil-
ity of allicin and, hence, the ability of garlic supplements to
represent fresh garlic.
The contents of the organosulfur compounds are varying
depending on the garlic cultivars [59]. The results of the
determination of the organosulfur compounds in two vari-
eties of Iranian garlic [Allium sativum var. sativum (I) and
Allium sativum var. holmense (II)] are cited below. The
organosulfur compounds in (I) exhibiting a concentration
higher than 1% are diallyl sulfide (1.3%), diallyl disulfide
(8%), methyl allyl disulfide (19%), methyl allyl trisulfide
(3.2%), diallyl trisulfide (5.5%), diallyl tetrasulfide (2%),
2,3-dimethyl thiophen (1.8%), 5-methyl-1,2,3-thiadiazol
(5%), and 1,2-ditiolan-3-carboxilic acid (1.5%). The
amount of organosulfur compounds in (II) are diallyl disul-
fide (2%), methyl allyl trisulfide (6.3%), diallyl tetrasulfide
(5%), and cyclopentanthiol(2.5%).
The protein content in garlic is about 3.1%. The electro-
phoretic patterns of the fresh garlic samples based on the
SDS-PAGE system are separated into numerous compo-
nents (37 bands). The molecular weight range of detected
components ranges from10to205 kDa. The majorityof the
protein bands were in molecular weight range of 24–
97 kDa.Inallexaminedpatternstwoduplicated,moreinten-
sivemajorcomponents(50and12 kDa)weredetected[60].
The free amino acid content of garlic samples as eval-
uated in two garlic subspecies Allium sativum L. var. opio-
scorodon (hardneck) and Allium sativum L. var. sativum
(softneck) ranged from 1121.7 to 3106.1 mg/100 g of fresh
weight (mean = 2130.7 l 681.5 mg/100 g). Hardneck garlic
had greater methiin, alliin, and total free amino acids con-
tents compared to softneck garlic. The major free amino
acid present in all but one subspecies was glutamine (cv.
Mother of Pearl contained aspartic acid as the major free
amino acid). Cv. Music Pink garlic (a rocambole hardneck
variety) contained the most methiin, alliin, and total free
amino acids [61].
The vitamins A, C, E, B-complex, tocopherols and ribo-
flavin were detected in garlic [60]. The concentrations of
essential trace elements in raw garlic are 556.1, 446.9,
143.3, 5.5 and 2.5 lg in 100 g fresh weight (FW), for zinc,
manganese, copper, selenium and iodine, respectively [60].
The contents of total polyphenols, total and a-tocopherols
in raw garlic are high: 120–130, 103.1 and 84.9 mg/100 g
FW,respectively[62].
Dietary fibers exercise a plasma cholesterol-lowering
effect. The content of total, insoluble and soluble dietary
fibers in edible parts of fresh garlic is 23.1 l 2.1, 14.9 l 1.2
and 8.2l 0.6 g/kg, respectively [60].
The most used garlic preparations are raw garlic per se,
aged garlic, garlic oil and commercially prepared lyophi-
lized garlic powder, garlic oil, garlic oil macerate and aged
garlic extract [63]. Aged garlic is sliced raw garlic stored
for20 monthsin15–20%ethanol.Thisprocesscauses con-
siderable loss of allicin and increased activity of certain
newer compounds, like S-allylcysteine (SAC), S-allylmer-
captocysteine, allixin and selenium that are stable, highly
bioavailable and significantly antioxidant [53].
Nowadays consumers prefer to use commercially pre-
pared garlic. The commercial garlic is prepared by the pro-
ducers from frozen lyophilized raw garlic samples. The
lyophilized garlic is transformed into powder, and in this
form is used by the consumers. From 1 kg of raw garlic,
250 g of powdered lyophilized garlic is received[62].
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The essential oil contentof garlic clovesis 0.2–0.5% and
consists of a variety of sulfides, such as DADS and diallyl
trisulfide. Eighty percent of the total lipids consists of four
fatty acids (FA): linoleic (46–53%), palmitic (20–23%),
oleic (4–13%) and a-linolenic acid (3–7%). About 70
other FAwere determined, 14 of them above 0.4% and only
4 above 2.5% [64]. Medicinally used garlic oil is mostly
prepared by steam distillation process. Steam-distilled gar-
lic oil consists of diallyl (57%), allyl methyl (37%) and
dimethyl(6%)monotohexasulfides.Atypicalcommercial
preparation of garlic oil contains diallyl disulfide (DADS,
26%), diallyl trisulfide (DATS, 19%), allyl methyl trisul-
fide (15%), allyl methyl disulfide (13%), diallyl tetrasul-
fide (8%), allyl methyl tetrasulfide (6%), dimethyl trisul-
fide (3%), penta sulfide (4%)and hexasulfide (1%)[53].
In pickled garlic, the contents of bioactive compounds
are different: salt content ranged from 2.39 to 7.40% and
water, protein, and dietary fiber – 86.89%, 3.35%, and
2.1%, respectively. The concentrations (wet weight basis)
of other major components are: fat (0.21–0.35%), ash
(2.65–8.40%), and sugars (2.21–4.22%). The levels of
vitamins: thiamine, 0–0.055 mg/kg, riboflavin, 0.013–
0.032 mg/kg, a-tocopherol, 0.36–2.53 mg/kg and ascorbic
acid, 0–47.9 mg/100 g [65]. Processing with and without
fermentation changes contents of garlic components. On a
dry basis, the fermented product had a higher content of
riboflavin, a-tocopherol, and most individual amino acids
but a lower thiamin level than the unfermented product.
Ascorbic acidis totallylost duringprocessing[66].
In order to be an effective remedy for atherosclerosis,
garlichastobeplasmacholesterol-lowering,plasmaantico-
agulant and antioxidant increasing agent and be able to pro-
tect the endothelial function of arteries. In the following
review of the recently published reports we are trying to
find out if garliccould bea cardioprotectiveagent.
4.3 Garlicand plasma hyperlipidemia
Hyperlipidemia is the major risk factor of atherosclerosis
and the lowering of its level together with increase in
plasma anticoagulant and antioxidant activities decreases
the morbidity and mortality from this disease [67, 68]. The
most studied and reported health-promoting effect of garlic
is cardioprotective, which includes the three above-men-
tioned properties and first of all plasma lipid-decreasing
effect [69, 70]. In a comprehensive review, 10 experiments
of garlic supplementation in laboratory animals and 11
investigations of humans were reported, most of which con-
firmed lipid-lowering effect of this vegetable [53]. In the
following 4 years after the above-mentioned review the
results of new trials were published. We have chosen only
four of them, which are connected by use of raw and boiled
garlic in experiments on rats [62, 71–73]. In the below-
cited animal trials the lipid-lowering effect of diets supple-
mented with rawor boiled garlic inrats fed cholesterol-con-
taining diets was demonstrated [62, 71, 72]. In all these
experiments the same protocol was used: (i) Wistar male
rats were randomly divided into control and experimental
groups; (ii) the rats of the control group were fed basal diet
(BD) that included wheat starch, casein, soybean oil, cellu-
lose, mineral, and vitamin mixtures; (iii) raw or boiled gar-
lic was administered orally; (iv) the duration of the experi-
ments was 28–30 days. To the BD of the experimental
groups, 25 mg of lyophilized garlic (equivalent to 500 mg
raw garlic/kg body weight) or garlic boiled for 20, 40 and
60 min and 1% of cholesterol was added. After the trial in
the groups of rats, whose diets were supplemented with raw
or boiled for 20 min garlica significant hinderingin the rise
in plasma lipids was registered: total cholesterol (TC),
20.1–26.8%, LDL-C, 39.3–54.2% and triglycerides, 8.6–
17.3%, and TC in liver, 27.2–35.7%. No significant
changes were found in the level of HDL-C. Addition of gar-
lic boiled for 40 and 60 min did not affect plasma and liver
lipid levels.
Based on the results of these experiments the authors
concluded that only raw or boiled for 20 min garlic pos-
sesses plasma lipid-lowering properties.
In the next experiment, raw and boiled aqueous extracts
of garlic were administered daily to normal rats both orally
and intraperitoneally for 4 weeks [73]. The serum levels of
glucose, cholesterol, and triglycerides were measured.
When the rats were treated with a low dose (50 mg/kg) of
raw aqueous extract of garlic, no significant changes in the
serumglucose levelswereobservedcomparedwiththecon-
trol group. However, therewas a significant reduction in the
cholesterol level of rats receiving a low dose of garlic (11–
14%). Rats receiving garlic orally and intraperitoneally also
showed a significant reduction in triglyceride levels (38%).
When the rats were treated with a high dose (500 mg/kg) of
raw garlic, glucose,cholesterol, and triglyceride levelswere
significantly affected. When boiled garlic extracts were
administered at high concentrations (500 mg/kg), there was
no effect on the level of serum glucose. However, a rela-
tively small but significant decrease in the concentration of
cholesterol and triglycerides was observed in the serum of
the rats receiving boiled garlic. The authors concluded that
raw garlic had a profound effect in reducing the glucose,
cholesterol, and triglyceride levels, whereas boiled garlic
had little effect incontrolling these parameters.
In the investigations of humans not only raw and aged
garlic extract (AGE) but also different medicinal prepara-
tions of garlic were used. Therefore, Russian investigators
studied effects of allicor (a long-acting garlic drug) on the
risk of coronary artery disease (CAD) [74]. They examined
167 patients with hyperlipidemia free of CAD. In men,
intake of allicor for 12 months resulted in a 10.7% reduc-
tion of a 10-year absolute risk to develop CAD (p a 0.05)
and decreased a 10-year absolute risk of acute myocardial
infarction and sudden death by22.7%(p a 0.05). In women,
allicor prevented age-related cardiovascular risk (p a 0.05).
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Among lipid parameters, the greatest decrease was
observed for total and LDL-C cholesterol (p a 0.05) by 27.9
and 22.5 and 11.4 and 10.8 mg/dL for men and women,
respectively.
A recently published study described the investigation of
diabetic patients suffering from hyperlipidemia [75]. A
clinical trial was performed in a group of 50 type 2 diabetic
patients (39 women, 11 men, cholesterol concentration
greater than or equal to 220 mg/dL) to assess the effect of
garlic powder tablet on blood glucose, lipid profiles and
blood pressure. Each patient received tablets containing
300 mg of garlic powder three times per day for 6 weeks. In
the beginning of the study and after 6 weeks supplementa-
tion of garlic powder tablets, blood pressure, fasting blood
glucose, glycated hemoglobin and lipid profiles were meas-
ured. After the trial, the following results were registered: a
significant decrease in TC (p a 0.01), LDL-C (p a 0.001),
systolic blood pressure (p a 0.03) and a significant increase
(p a 0.02) in HDL-C. No significant changes in diastolic
blood pressure, fasting blood sugar, serum triglycerides and
HbA1c were found.
Not only above-cited individual trials confirmed the
lipid-lowering effect of garlic and its preparations. There-
fore, Stevinson et al. [76] search revealed 39 garlic trials in
the literature. Thirteen of these trials provided data suitable
for statistical pooling. Other were excluded because they
were not placebo-controlled, were not randomized,were not
double-blind, did not test a monopreparation, did not report
total cholesterol levelor reported a mean baseline total cho-
lesterol levelless than 5.17 mmol/L (200 mg/dL). A total of
796 persons were involved in his research. Baseline values
(mean l SD) in the garlic groups ranged from 5.78 l
1.06 mmol/L (223 l 41 mg/dL) to 7.72 l 3.37 mmol/L (298
l 130 mg/dL). In the placebo groups, the baseline values
ranged from 5.62 l 0.70 mmoI/L (217 l 27 mg/dL) to 7.64
l 1.55 mmol/L (295 l 60 mg/dL). Ten trials report mean
differences that favor garlic over placebo. Only three trials
show95%CIthatdonotoverlapthelineofzeroeffect,indi-
cating significant differences. Meta-analysis of all trials
indicated a significant difference (p a 0.01) in the reduction
of total cholesterol level from baseline in favor of garlic
compared with placebo. The weighted mean difference was
–0.41 mmol/L (95% CI, –0.66 to –0.15 mmol/L) and
(–15.7 mg/dL [CI, –25.6 to –5.7 mg/dL]), respectively.
This is equivalent to a 5.8% reduction in total cholesterol
levelsfrom baseline due togarlic.
The meta-analysis of the authors focused on the effect of
garlic on total cholesterol level. However, because five of
the trials also presented other lipid data, they were analyzed
to provide an indication of the effect on garlic on HDL and
LDL cholesterol levels. The results indicated a nonsignifi-
cant difference in the reduction of LDL cholesterol levels
between garlic and placebo and a nonsignificant difference
in the increase of HDL cholesterol between garlic and pla-
cebo. The weighted mean differences were –0.17 mmoI/L
(CI, –0.35 to 0.01 mmol/L) (–6.6 mg/L [CI, –13.5 to 0.4
mg/dL]) and 0.07 mmol/L (CI. –0.10 to 0.2 mmol/L)
(2.7 mg/dL [CI, –3.9to8.9 mg/dL]), respectively [76].
In the very recently published article of Gardner et al.
[77] the effect of raw garlic vs. commercial garlic supple-
ments on plasma lipid concentration in adults with moder-
ate hypercholesterolemiawas described.
The cited experiments in vivo and investigations of
humans show that garlic and its preparations possess
plasma lipid-lowering properties.
Despite the reported hypocholesterolemic effect of gar-
lic, the mechanism of this effect is still unclear [78]. In a
randomized, double-blind, placebo-controlled intervention
study, these authors showed that AGE supplementation was
effective in lowering plasma concentration of TC by 7%
andLDL-Cby10%inhypercholesterolemic mencompared
with subjects consuming placebo. Supplementation of AGE
to animal diets similarly reduced plasma concentrations of
TC and triglycerides by 15 and 30%, respectively. In subse-
quent experiments using cultured rat hepatocytes, they
found 44–87% inhibition of cholesterol synthesis by the
water-extractable fraction (WEF), methanol-extractable
fraction (MEF) and petroleum ether extractable fraction
(PEF) of fresh garlic, and Kyolic (liquid form of AGE).
They observed that hydrophilic and hydrophobic com-
pounds of garlic are inhibitory to cholesterol synthesis.
Because S-allylcysteine (SAC) alone was less potent than
Kyolic, which contains SAC and other sulfur compounds, a
maximal inhibition appears to require a concerted action of
multiple compounds of garlic. In a series of experiments,
water-soluble compounds SAC, S-ethylcysteine (SEC), and
S-propylcysteine (SPC) inhibited cholesterol synthesis by
40–60% compared with 20–35% by c-glutamyl-S-allyl-
cysteine (GSAC), c-glutamyl-S-methylcysteine (GSMC)
and c-glutamyl-S-propylcysteine (GSPC). Lipid-soluble
sulfur compounds (i.e. diallyl sulfide, diallyl disulfide, dia-
llyl trisulfide, dipropyl sulfide and dipropyl trisulfide) at
low concentrations (0.05–0.5 mol/L) slightly (10–15%)
inhibited cholesterol synthesis but became highly cytotoxic
at high concentrations (1.0–4.0 mol/L). The authors con-
cluded that the cholesterol lowering effects of garlic
extracts, such as AGE, stem in part from inhibition of hep-
atic cholesterol synthesis by water-soluble sulfur com-
pounds, especially SAC.
There are also other investigations, which explore the
principal mechanism by which garlic decreases cholesterol
levels [79]. These authors claim that garlic decreases cho-
lesterol by inhibition of sterol 4a-methyl oxidase. In order
to identify the principal site of inhibition in the cholesterol-
genic pathway and the active components of garlic, they
have treated with aqueous garlic extract or its chemical
derivatives cultured hepatoma cells and identified and
quantified radiolabeled cholesterol and intermediates. The
used extract reduced cholesterol synthesis by up to 75%
without evidence of cellular toxicity. Levels of squalene
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and 2, 3-oxidosqualene were not altered by garlic, indicat-
ing that the site of inhibition was downstream of lanosterol
synthesis, and identical results were obtained with
14C-ace-
tate and
14C-mevalonate, confirming that 3-hydroxy-3-
methylglutaryl-CoA reductase activity was not affected in
these short-term studies. Several methylsterols that accu-
mulated inthe presence of garlic were identifiedbycoupled
GC–MS as 4, 49-dimethylzymosterol and a possible metab-
olite of 4-methylzymosterol; both are substrates for sterol
4a-methyl oxidase, pointing to this enzyme as the principal
site of inhibition in the cholesterolgenic pathway by garlic.
Of nine garlic-derived compounds tested for their ability to
inhibit cholesterol synthesis, only diallyl disulfide, diallyl
trisulfide, and allyl mercaptan proved inhibitory. The
results of this investigation indicate that compounds con-
taining an allyl-disulfide or allyl-sulfhydryl group are most
likely responsible for the inhibition of cholesterol synthesis
by garlic and that this inhibition is likely mediated at sterol
4a-methyloxidase.
All above-cited investigations demonstrated the choles-
terol-lowering effect of garlic and its preparations. How-
ever, also the negative results of garlic treatment, which are
described belowshould bementioned.
No effect of garlic therapy on major plasma lipoproteins
was shown by Superko and Krauss [80]. These two investi-
gators tested the hypothesis that a garlic supplement alters
plasma lipids in 50 moderately hypercholesterolemic sub-
jects. A double blind, randomized, placebo-controlled trial
in an outpatient lipid research clinic was performed. The
results of this investigation showed that garlic therapy has
no effect on major plasma lipoproteins and further, that it
has noimpactonHDL subclasses.
The next cited study also cast doubt on the lipid-lower-
ing effect of garlic [81]. The effect of dried garlic powder
on blood lipids, blood pressure and arterial stiffness in a
12-week randomized, double blind, placebo-controlled trial
was tested. Seventy-five healthy, normolipidemic volun-
teers (men and women aged 40–60 years) were assigned to
dried garlic powder tablets (10.8 mg alliin (3-(2-propenyl-
sulfinyl)-L-alanine)/d, corresponding to about three garlic
cloves) or placebo. The primary outcome measure was
serum total cholesterol concentration. Secondary outcome
measures were LDL-cholesterol, HDL-cholesterol and tri-
glycerides concentrations, blood pressure and arterial stiff-
ness assessed by pulse wave velocity. No significant differ-
ences between the garlic and placebo groups were detected
for any of the outcome measures. In conclusion, garlic
powder tablets have no clinically relevant lipid- and blood
pressure-lowering effects in middle-aged, normolipidemic
individuals. The putative anti-atherosclerosis effect of gar-
lic may be linked to risk markers other than blood lipids
[81].
In addition, no positive results from garlic consumption
on lipid profile in people with mild to moderate hypercho-
lesterolemia were observed by Israeli investigators [82].
Therefore Kerckhoffs et al. [83] claim that it is still uncer-
tain whether garlic or garlic preparations can be used as
lipid-lowering agents.
Itmustbeunderlinedthatthelipid-loweringeffectofgar-
lic is dose dependent (Table 1).
As can be seen only the dose equivalent to 500 mg/kg
body weight led to significant decrease in the level of the
plasma lipids [71].
Therefore, one of the reasons of the negative results
could be awrong dose of garlic.
4.4 Garlicand plasma antioxidant activity
As was already stated, in order to be effective cardioprotec-
tiveagent garlichas topossess also antioxidantproperties.
It has been shown that raw garlic and AGE contain anti-
oxidant phytochemicals that prevent oxidant damage [84].
Among them unique water-soluble organosulfur com-
pounds, lipid-soluble organosulfur components and flavo-
noids, notably allixin and selenium. Long-term extraction
of garlic (up to 20 months) ages the extract, creating antiox-
idant properties by modifying unstable molecules with anti-
oxidant activity, such as allicin, and increasing stable and
highly bioavailable water-soluble organosulfur compounds,
such as S-allylcysteine and S-allylmercaptocysteine. AGE
exerts antioxidant action by scavenging reactive oxygen
species (ROS), enhancing the cellular antioxidant enzymes
superoxide dismutase, catalase and glutathione peroxidase,
and increasing glutathione in the cells. AGE inhibits lipid
peroxidation, reducing ischemic/reperfusion damage and
inhibiting oxidative modification of LDL, thus protecting
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Table 1. Plasma lipids (mmol/L) and total cholesterol in liver (lmol/g) in rats fed diets supplemented with raw garlic in dose of 500,
750 and 1000 mg/kg body weight and 1% cholesterola)
Diets TC LDL-C HDL-C TG TCin liver
Chol 3.69l 0.21
a) 2.08l 0.12
a) 1.61 l0.07
a) 0.88l 0.05
a) 24.1l 1.2
a)
Gar500/Chol 2.81l 0.17
b) 1.19l 0.05
b) 1.62 l0.07
a) 0.75l 0.05
b) 17.7l 0.9
b)
Gar750/Chol 3.45l 0.18a) 1.81l 0.05a) 1.64 l0.07a) 0.83l 0.05a) 22.9l 1.0a)
Gar1000/Chol 3.60l 0.18
a) 1.99l 0.05
a) 1.61 l0.07
a) 0.86l 0.05
a) 23.1l 1.1
a)
a) Values are means l SD, n = 7. Means in columns without letters in common differ significantly (p a 0.05). Abbreviations used:
Chol, nonoxidizedcholesterol; Gar, garlic; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; TC, total cholesterol; TG, triglycer-
ides.Mol. Nutr. Food Res. 2007, 51,1365–1381
endothelial cells from the injury by the oxidized molecules,
whichcontributestoatherosclerosis [84].
Not only AGE possesses antioxidant activity. In addition,
the extract of garlic skins (peels) has the same properties
[85]. In this study, the 1,1-diphenyl-2-picrylhydrazyl
(DPPH) radical scavenging activity of garlic skin extract
was evaluated. The active constituents were isolated and
subsequently identified by chromatographic techniques.
Analysis by HPLC coupled with a photodiode array detec-
tor (HPLC-PDA) suggests that these compounds were phe-
nylpropanoids, which had a characteristic absorbance at
300–320 nm. LC-MS and NMR analyses allowed the
chemical structures of the isolated constituents to be postu-
lated. The proposed compounds were subsequently synthe-
sized and compared with the constituents in the extract
using HPLC-PDA and LC-MS. N-trans-coumaroyloctop-
amine, N-trans-feruloyloctopamine, guaiacylglycerol-beta-
ferulic acid ether, and guaiacylglycerol-beta-caffeic acid
ether were identified aswere trans-coumaric acid and trans-
ferulic acid [85].
The antioxidant properties of four main chemical classes
of garlic, alliin, allyl cysteine, allyl disulfide, and allicin,
prepared bychemical synthesis or purificationwereinvesti-
gated [86]. Alliin scavenged superoxide, while allyl cys-
teine and allyl disulfide did not react with superoxide. Alli-
cin suppressed the formation of superoxide by the xanthine/
xanthine oxidase system, probably via a thiol exchange
mechanism. Alliin, allyl cysteine, and allyl disulfide all
scavenged hydroxyl radicals. Allyl disulfide, alliin, allicin,
and allyl cysteine exhibit different patterns of antioxidant
activities as protectivecompounds against free radical dam-
age.
In addition, the next experiment in vitro tested whether
fresh and commercial shallot and garlic preparations have
antioxidant properties [87]. Samples produced by pressing
and extraction of bulbs were tested for their ability to
decrease free radicals of 2,29-azinobis (3-ethylbenzothiazo-
line-6-sulfonic acid) and the results were compared with
commercial preparations of aged garlic and with trolox,
butylated hydroxytoluene, N-acetyl cysteine, and gallic
acid. The phenolic content of the extracts and the amounts
of diallyl sulfides present also were measured. The authors
proved that antioxidant activities were directly related to
the contents of phenolic compounds, with the fresh freeze-
dried extracts significantly more potent than commercial
preparations. Hexane-extracted shallot and garlic had the
highest antioxidant activity, followed by water extracts,
bulbpressings, and commercial products[87].
In order to compare the antioxidant properties of differ-
ent garlic preparations their antioxidant potential has to be
determined [60, 62,71, 72].
The above mentioned authors have determined antioxi-
dant potential of raw and boiled garlic by different assays:
b-carotene linoleate model system (b-carotene) [88]; radi-
cal scavenging activity by 1, 1-diphenyl-2-picrylhydrazyl
(DPPH) [88]; scavenging activity against nitric oxide (NO)
[89, 90], with 2, 29-azinobis (3-ethylbenzothiazoline-6-sul-
fonic acid) radical cation (ABTS
+) [91], ferric-reducing/
antioxidant power (FRAP) and cupric reducing antioxidant
capacity (CUPRAC).
In addition, other authors found that the antioxidant
potentialofgarlichomogenatesblendedwithdistilledwater
and different amounts of soybean oil was strong and diallyl
disulfide was the most stable among the three sulfur com-
pounds of garlic (allicin, diallyl disulfide, and diallyl trisul-
fide) [92].
Based on combined data of ten published papers [71, 72,
91, 93–99] the place of garlic according to antioxidant
potential among other popular vegetables is shown in the
Table 2. As can be seen, according to antioxidant potential,
red pepper F green pepper = garlic = onion F white cab-
bage.
The results of the determination of the antioxidant poten-
tial by different antioxidant assays as shown in the Table 2
are different. In addition, other authors reported the same
differences [100]. They found that antioxidant potential of
the studied by them vegetables could be put in following
order: red pepper A green pepper A white cabbage A white
onion and green pepper A red pepper A white onion A white
cabbage forFRAPand ORAC assays, respectively.
Siegel et al. [101] claim that deposition of lipoproteins
and their protein components (apolipoproteins), notably
LDL at the surface of endothelial cell membranes and con-
nectivetissue matrices inblood vesselsconstitute one of the
initial steps of atherosclerosis. Proteoheparan sulfate can be
adsorbed to a methylated silica surface in a monomolecular
layer via its transmembrane hydrophobic protein core
domain. This binding process was studied by using ellipso-
metric techniques. It was shown that HDL has a high bind-
ingaffinity tothereceptor and aprotectiveeffect oninterfa-
cial heparan sulfate proteoglycan layers, with respect to
LDL and Ca
2+ complexation. LDL was found to deposit
strongly at the proteoheparan sulfate, particularly in the
presence of Ca
2+, thus creating the complex formation, pro-
teoglycan-low density lipoprotein-calcium’. This ternary
complex build-up may be interpreted as arteriosclerotic
nanoplaque formation on the molecular level responsible
for the arteriosclerotic primary lesion. On the other hand,
HDL bound to heparan sulfate proteoglycan protected
against LDL docking and completely suppressed calcifica-
tion of the proteoglycan-lipoprotein complex. In addition,
HDL and aqueous garlic extract were able to reduce the ter-
nary complex deposition and to disintegrate HS-PG/LDL/
Ca
2+aggregates.
In the next investigation of Siegel et al. [102] the studied
an in vitro biosensor model (PCT/EP 97/05212), the inter-
play between different lipoproteins in arteriosclerotic nano-
plaque formation, as well as aqueous garlic extract (0.2–
5.0 g/L from LI 111 powder) as a possible candidate drug
against arterio/atherosclerosis. These processes were stud-
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ied by ellipsometric techniques quantifying the adsorbed
amount (nanoplaque formation) and layer thickness (nano-
plaque size). It has been found that proteoheparan sulfate
(HS-PG) adsorption to hydrophobic silica was monoexpo-
nential and after approximately 30 min constant. The addi-
tion of 2.52 mmol/L Ca
2+ led to a further increase in HS-PG
adsorption because Ca
2+was bound to the polyanionic gly-
cosaminoglycan (GAG) chains, thus screening their nega-
tive fixed charges and turning the whole molecule more
hydrophobic. Incubation with 0.2 g/Ll aqueous garlic
extract (GE) for 30 min did not change the adsorption of
HS-PG. However, the following addition of Ca
2+ ions
reduced the increase in adsorption by 50.8% within 40 min.
The adsorption of a second Ca
2+step to 10.08 mmol/L was
reduced by even 82.1% within the next 40 min. This inhibi-
tion of receptor calcification shows that the build-up of the
ternary nanoplaque complex is also affected by garlic. Sie-
gel et al. [102] concluded that their experiments clearly
proved that garlic extract strongly inhibits Ca
2+ binding to
HS-PG. In consequence, the formation of the ternary HS-
PG/LDL/Ca
2+ complex, initially responsible for the ,nano-
plaque’ composition and ultimately for the arteriosclerotic
plaquegeneration, is decisivelyblunted.
Oxidation of LDL has been recognized as playing an
important role in the initiation and progression of athero-
sclerosis [7, 8]. Oxidized LDL, but not native LDL, pro-
motes vascular dysfunction by exerting direct cytotoxicity
toward endothelial cells, by increasing chemotactic proper-
ties for monocytes, by transforming macrophages to foam
cells via scavenger-receptors and by enhancing the prolifer-
ation of various cell types, e.g. endothelial cells, monocytes
and smooth muscle cells; all of these events are recognized
as contributing to atherogenesis [103, 104]. These authors
found experimental evidence that several garlic compounds
can effectively suppress LDL oxidation in vitro and that
short-term supplementation of garlic to humans increases
resistance of LDLto oxidation.
In the next experiment in vitro, human LDL was isolated
and challenged with a range of oxidants either in the pres-
ence or in the absence of AGE or its diethyl ether extract
[105].
Oxidative modification of the LDL fraction using
CuSO4, 5-lipoxygenase and xanthine/xanthine oxidase was
monitored by both the appearance of thiobarbituric-acid
substances (TBA-RS) and an increase in electrophoretic
mobility. This study indicates that AGE is an effective anti-
oxidant as it scavenged superoxide ions and reduced lipid
peroxide formation in cell-free assays. Superoxide produc-
tion was completely inhibited in the presence of a 10% v/v
aqueous preparation of AGE and reduced by 34% in the
presence of a 10% v/v diethyl ether extract of AGE. The
presence of 10% v/v diethyl ether extract of AGE signifi-
cantly reduced Cu
2+ and 15-lipoxygenase-mediated lipid
peroxidation of isolated LDL by 81% and 37%, respec-
tively. In addition, it was found that AGE also had the
capacity tochelatecopper ions.Incontrast,thediethylether
extract of AGE displayed no copper binding capacity, but
demonstrated distinct antioxidant properties. These results
support the view that AGE inhibits invitro oxidation of iso-
lated LDL by scavenging superoxide and inhibiting the for-
mation of lipid peroxides. AGE was also shown to reduce
LDL oxidation bythe chelation of Cu
2+[105].
The effects of onion and garlic juices on biochemical
parameters, enzyme activities and lipid peroxidation were
studied also in vivo on alloxan-induced diabetic rats [106].
A dose of 1 mL of either onion or garlic juices/100 g body
weight was orally administered daily to alloxan-diabetic
rats for 4 weeks. It was found that both garlic and onion jui-
ces possess antioxidant and anti-hyperglycemic properties.
In most of experiments whole garlic was used. Gonen et
al. [107], in their study evaluated the antioxidant effects of
pure allicin on atherogenesis in experimental mouse mod-
els. Daily dietary supplement of allicin, 9 mg/kg body
weight, reduced the atherosclerotic plaque area by 68.9 and
56.8% in apolipoprotein E-deficient and LDL receptor
knockout mice, respectively, as compared with control
mice. LDL isolated from allicin-treated groups was more
resistant to CuSO4-induced oxidation ex vivo than LDL iso-
lated from control mice. Incubation of mouse plasma with
3H-labeled allicin showed binding of allicin to lipoproteins.
By using electron spin resonance, authors demonstrated
reduced Cu
2+ binding to LDL following allicin treatment.
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Table 2. The antioxidant potentials of garlic and some other popular vegetables
a)
Samples ORAC
(lmol TE/gFW)
FRAP
(lmol Fe
2+/gFW)
b-carotene
(inhibition,%)
DPPH
(RSA%)
TEAC
(lmolTE/gFW)
Garlic(Allium sativum) 8.7–8.9 1.9–2.7 71.8–72.7 62.1–66.1 2.5–3.3
Whiteonion(Allium sepa) 10.2–11.2 4.3–8.5 67.4–68.2 31.1–32.9 1.8–3.5
Greenpepper(Pipergen.) 5.5–6.3 13.2–15.6 70.4–71.2 61.1–62.1 6.1–7.2
Redpepper(Pipergen.) 9.01–10.3 18.1–20.9 73.4–78.2 65.1–68.1 7.8–8.1
Whitecabbage(Brassica
oleraceacapipata)
11.1–13.6 0.7–1.6 52.5–53.9 49.6–51.3 1.7–1.9
a) Values are means of five measurements. Abbreviations used: b-carotene, b-carotene linoleate model system; DPPH, radical
scavenging activity by 1,1-diphenyl-2-picrylhydrazyl; FRAP, ferric-reducing/antioxidant power; ORAC, oxygen radical absorption
capacity; RSA, radical scavenging activity; TEAC, trolox equivalent antioxidant capacity.Mol. Nutr. Food Res. 2007, 51,1365–1381
LDL treatment with allicin significantly inhibited both
native LDL and oxidized LDL degradation by isolated
mouse macrophages. The authors concluded that pure alli-
cin preparation affect atherosclerosis not only by acting as
an antioxidant, but also by other mechanisms, such as lipo-
protein modificationand inhibition of LDL uptake and deg-
radation by macrophages.
The changes in garlic antioxidant properties subjected to
temperature were addressed by some investigators [60,
108]. It was shown that garlic subjected to boiling temper-
ature for more than 20 min losses a significant part of its
antioxidant ability [60]. However, not all investigators con-
firm these findings. Pedraza-Chaverri' et al. [108] studied
theabilityofaqueous garlicextractstoscavengesuperoxide
anion (O2 9
–), hydrogen peroxide (H2O2), and hydroxyl radi-
cal (OH9) in the following aqueous preparations: (a)
extracts of boiled garlic cloves (BG), (b) extracts of micro-
wave-treated garlic cloves (MG), and (c) extracts of pickled
garlic (PG), and heated extracts of (a) garlic powder (HGP)
and (b) raw garlic (HRG). The datawere compared with the
unheated raw garlic (RG) or with the unheated garlic pow-
der (GP). Extracts of GP and RG scavenged O2 9
–,H 2O2, and
OH9inaconcentration-dependent way.Thereactive oxygen
species scavenging capacity was not decreased in the aque-
ous garlic extracts except in MG and HRG (for O2 9
–) and in
HGP and PG (for H2O2). The heating before or after garlic
cutting was unable to eliminate the capacity of the extracts
toscavenge H2O2,O 2 9
–,and OH9[108].
As was cited, the oxidation of LDL has been recognized
as playing an important role in the initiation and progres-
sion of atherosclerosis. All above cited studies in vitro and
invivoshow thatgarlic possesses strongantioxidantproper-
ties and therefore has an important role in atherosclerosis
prevention.
4.5 Garlicand plasma anticoagulantactivity
Arterial thrombosis is playing a leading role in the death
rate from coronary atherosclerosis: in more than in 80%
patientswithacutetransmuralinfarctionofthemyocardium
thrombotic occlusion of coronary artery was found [109].
Detailed knowledge of the pathophysiology as well as the
dynamic nature of coronary thrombus formation provides a
valuabletoolforcorrectmanagement and properadjunctive
therapy. Coronary thrombosis is in the majority of cases
caused by disruption or fissuring of an atherosclerotic pla-
que. At the lesion thrombogenic material is exposed to the
flowing blood leading to activation of platelets and the for-
mation of a platelet clot. Simultaneously, the coagulation
system is activated resulting in increased thrombin forma-
tion. Thrombin is a key mediator in arterial thrombosis, due
to its effect on both platelets and fibrin generation. Throm-
bin contributes to the stabilization of an initially loose pla-
telet clot by generating cross-bound fibrin within the
thrombus [110]. Therefore, in order to prevent arterial
thrombus formation the anticoagulant system must be acti-
vated. Recently published papers show the influence of gar-
lic onanticoagulant system.
Antithrombotic effect of garlic consumption is one of the
best-investigated [111]. Among the most studied indices of
antithrombotic effect is the reduction of the platelet aggre-
gation by garlic and its preparations [112, 113]. A 13-week
study was performed in normolipidemic subjects who
ingested 5 mL of AGE, Kyolic per day. Aggregation of pla-
telet-rich plasma was induced by ADP. Dietary supplemen-
tation with AGE significantly inhibited both the total per-
centage and initial rate of platelet aggregation at concentra-
tions of ADP up to 10 lmol/L. The KM for ADP-induced
aggregation was approximately doubled after supplementa-
tion with AGE, whereas the maximum rate of aggregation
was unaffected. Therefore, AGE, when taken as a dietary
supplement by normolipidemic subjects, may be beneficial
in protecting against cardiovascular disease as a result of
inhibiting platelet aggregation [114].
A meta-analytical survey based on 11 electronic data-
bases, references, manufacturers, and experts from January
1966 through February 2000 has been published [112]. The
authors included 1798 pertinent records, 45 randomized tri-
als and 73 additional studies. Reports of cardiovascular-
related effects were limited to randomized controlled trials
lasting at least 4 weeks. Two physicians abstracted out-
comes and assessed adequacy of randomization, blinding,
and handling of dropouts. Standardized mean differences of
lipid outcomes from placebo-controlled trialswere adjusted
for baseline differences and pooled using random effects
methods.Ithasbeenfoundthatincomparisonwithplacebo,
garlic preparations lead to a significant reduction in platelet
aggregation [112].
The underlying mechanism of the platelet aggregation
inhibition by AGE was described in the next study [113].
Because calcium mobilization plays an important role in
platelet aggregation, the effect of AGE was investigated in
this preliminary study. ADP and the calcium ionophore
A23187 both stimulated platelet aggregation with a con-
comitant increase in intracellular calcium ion concentra-
tion. When these experimentswere repeated in the presence
ofAGE,bothplateletaggregationandcalciummobilization
were suppressed. In addition, when platelets were preincu-
bated with AGE, the initial concentration of intracellular
calcium was significantly reduced compared with platelets
without AGE, confirming the metal-chelating properties of
AGE. Platelets loaded with fura-2 acetoxymethyl ester
(fura-2 AM) also displayed a reduction in platelet aggrega-
tion, and the addition of external calcium did not alter this
observation. The data obtained in this study, suggest that
AGE probably exerts its inhibitory effect on platelet aggre-
gation either by suppressing the influx of calcium ions by
chelating calcium within platelet cytosol or by altering
other intracellular second messengers within the platelets
[113].
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In addition, other indices of the anticoagulant activity
were positively influence by commercial powdered garlic
[62]. The authors randomly divided Wistar rats into five
diet groups, named Control, Chol, Garlic500, Garlic750,
and Garlic1000. Control rats were fed basal diet (BD),
which included wheat starch, casein, soybean oil, and vita-
min and mineral mixtures. To the BD of the Chol group was
added 1% of cholesterol. To the BD of the other three
groups (Garlic500, Garlic750, and Garlic1000) were added
1% of cholesterol and commercial garlic equal to 500, 750,
and 1000 mg of raw garlic per kilogram of animal weight.
After 4 weeks of the experiment a significant decrease in
plasmacirculatingfibrinogenandanincreaseintheclotting
timewere found (Fig. 1). The fibrinogenolytic effect of gar-
lic diets was visualized by SDS-PAGE. In the fibrinogen
fraction of Garlic500 the 66, 24, and 14- kDa protein bands
were detected with weaker protein intensity than in the Gar-
lic750 and Garlic1000.
In a very recently published article, Cavagnaro et al.
[115] describe the effect of cooked garlic on anti-platelet
activity. They examined the in vitro anti-aggregatory activ-
ity (IVAA) of human blood platelets induced by extracts of
garlic samples that were previously heated (in the form of
crushed versus uncrushed cloves) using different cooking
methods and intensities. These authors also monitored the
concentrations of allicin and pyruvate, two predictors of
anti-platelet strength. Cavagnaro et al. [115] found that
oven-heating at 2008C or immersing in boiling water for
3 minorlessdidnotaffecttheabilityofgarlictoinhibitpla-
telet aggregation, whereas heating for 6 min completely
suppressedIVAA incrushedsamples.Prolongedincubation
(more than 10 min) at these temperatures completely sup-
pressed IVAA. Microwaved garlic had no effect on platelet
aggregation. However, increasing the concentration of gar-
lic juice in the aggregation reaction had a positive IVAA
dose response in crushed, but not in uncrushed, microwaved
samples. The addition of raw garlic juice to microwaved
uncrushed garlic restored a full complement of anti-platelet
activity that was completely lost without thegarlic addition.
Garlic-induced IVAA was always associated with allicin
and pyruvate levels. Cavagnaro et al. [115] concluded that
their results suggest that (i) allicin and thiosulfinates are
responsible for the IVAA response, (ii) crushing garlic
before moderate cooking can reduce the loss of activity, and
(iii) the partial loss of antithrombotic effect in crushed-
cooked garlic may be compensated by increasing the
amount consumed.
4.6 Garlicand endothelial function of arteries
Endothelial dysfunction of arteries in general and coronary
arteries in particular is considered an early phase of athero-
sclerosis and plays a key role in progression of this decease
[116, 117]. There is growing recognition that endothelial
dysfunction in addition to its role in early atherosclerosis,
also contributes to the later stages of the disease when
patients develop clinical symptoms [118]. It was shown in
experiments on laboratory animals [119] and investigations
of humans [120] that diets supplemented with garlic are
able torestore endothelial function.
In the in vivo experiment, rats were fed with 1% raw gar-
lic (RG) supplemented diet. In order to induce pulmonary
hypertension monocrotaline (MCT) injections were used.
In all cases, RG feeding prevented the exaggerated vaso-
constrictory responses of coronary arteries to MCT. How-
ever, similar treatments with either boiled garlic (BG) or
aged garlic (AG), which do not contain the active allicin
metabolite, were ineffective. Further testing of vasoactivity
to garlic extracts showed that only RG, but not BG or AG,
elicited a potent, dose-dependent dilation on the isolated
coronaries. These findings show that positive effect of RG
is probably mediated via its active metabolite allicin action
oncoronaryendothelial function and vasoreactivity[121].
Siegel et al. [122] have measured the electrophysiologi-
cal correlation to vasodilatation in human coronary arteries
under the influence of garlic extract. They observed that
between 0.0002 and 0.2 g powder/L extract concentration,
garlic had hyperpolarized the membrane of normal vascular
smooth muscle cells of the human coronary artery in a con-
centration-dependent manner. Correspondingly, the isomet-
ric wall tension was decreased. For the garlic constituents
allicin and ajoene, a similar course in membrane potential
and wall tension for aqueous solutions between 10
–9 and
10–6mol/L was obtained. These compounds hyperpolar-
ized the cell membrane and relaxed the vascular strips in a
concentration-dependent manner. In the author's opinion,
the hyperpolarization in vascular smooth muscle supports
the concept that garlic extract and its compounds can be
classified as phytopharmacological K
+channel openers.
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Figure 1. Total antioxidant capacity (mM TE/L) and
blood clotting time (min) in plasma samples of rats after garlic
and cholesterol diets. This figure is adapted from [71].Mol. Nutr. Food Res. 2007, 51,1365–1381
The endothelial dysfunction caused by increases in vas-
cular oxidant stress decreases bioavailability of nitric oxide
(NO) and thus plays a critical role in thevascular pathobiol-
ogy of hyperhomocysteinemia [123]. AGE contains water-
and oil-soluble sulfur compounds that modify the intracel-
lular thiol and redox state, minimize intracellular oxidant
stress, and stimulate NO generation in endothelial cells. In
a placebo-controlled, blinded, crossover trial in healthy sub-
jects it was examined whether AGE reduces macro- and
microvascular endothelial dysfunction during acute hyper-
homocysteinemia induced by oral methionine challenge.
Acute hyperhomocysteinemia leads to a significant
decrease in flow-mediated vasodilation of the brachial
artery as determined by vascular ultrasound, indicative of
macrovascular endothelial dysfunction. In addition, acute
hyperhomocysteinemia leads to a decrease in acetylcho-
line-stimulated skin perfusion as measured by laser-Dop-
pler flowmetry. Pretreatment with AGE for 6 weeks signifi-
cantly diminished the adverse effects of acute hyperhomo-
cysteinemia in both vascular territories. Therefore AGE
may at least partly prevent a decrease in bioavailability of
NO and endothelium-derived hyperpolarizing factor during
acute hyperhomocysteinemia [123].
The results of a short-term treatment with AGE also
proved that this natural product might improve impaired
endothelial function [120]. The aim of the investigators was
to test the effect of treatment with AGE on brachial artery
flow-mediated endothelium-dependent dilation (FMD) and
circulating markers of oxidative stress and systemic inflam-
mation. The trial included 15 men with angiographically
proven CAD in randomized, placebo-controlled, crossover
design with 2-week treatment and washout periods. During
AGE supplementation, FMD increased (44%) significantly
(p = 0.04) from the baseline and mainly in men with lower
baseline FMD. Levels of FMD at the end of AGE treatment
were significantly (p = 0.03) higher compared with the cor-
responding levels at the end of placebo treatment when the
variation in baseline body weight was taken into account.
Markers of oxidantstress (plasma oxidized LDL and perox-
ides), systemic inflammation (plasma C-reactive protein ad
interleukin-6) and endothelial activation (YCAM-1) did not
change significantly during the study. These data suggest
that even short-term treatment with AGE may improve
impaired endothelial function in men with CAD treated
withaspirin and a statin.
Therefore, all cited studies indicate that garlic is able to
improve animpaired endothelial function.
5 Conclusions
Garlic was used for many millennia as a cure for a wide
variety of different conditions. It was shown that garlic con-
tains a wide spectrum of bioactive compounds and high
antioxidant activity (Figs. 2 and 3) – the basis of its suc-
cessful use [124]. This bulbous rooty vegetable became
very popular and nowadays some researches claim that gar-
lic is able to cure practically all diseases. However, garlic is
not a panacea. Even the most enthusiastic supporters of this
1377
i 2007WILEY-VCH Verlag GmbH &Co. KGaA, Weinheim www.mnf-journal.com
Figure 2. Different radical scavenging assays of garlic (G)
samples during processing: NPG, non processed; PG1, PG2,
PG3, processed garlic at 1008C for 20, 40 and 60 min. FC,
polyphenols, lg/ 100g FW; FRAP, 1006mM/100 g; DPPH, %
inhibition. Values are means l SD of 5 measurements. Abbre-
viations: Folin-Ciocalteu (FC); Ferric Reducing/Antioxidant
Power (FRAP); 1,1-diphenyl-2-picrylhydrazyl (DPPH). This fig-
ure is adapted from [124].
Figure 3. Correlation coefficients for processed and non proc-
essed garlic (G) samples and their antioxidant capacities.
NPG, non processed; PG1, PG2, PG3, processed garlic at
1008C for 20, 40 and 60 min. (H)F C( lg/100g, X): NPG = 49.3
l 3.1a; PG1 = 45.1 l 3.0a; PG2 = 34.1 l 2.7b 32.4 l 2.6b; PG3 =
32.4 l 2.6
band FRAP (1006mmol/100g, Y1): NPG = 34 l 2.7
a;
PG1 = 31 l 2.6
a; PG2 = 23 l 2.1
b; PG3 = 22 l 2.1
b to (h)F C
(lg/100g, X): NPG = 49.3 l 3.1a; PG1 = 45.1l 3.0a; PG2 =
34.1l 2.7
b 32.4 l 2.6
b; PG3 = 32.4 l 2.6
b and DPPH (% inhibi-
tion, Y2): NPG = 69.2 l 5.1
a; PG1 = 68.1 l 5.0
a; PG2 = 49.3 l
3.1
b; PG3 = 47.5 l 3.1
b. Values are means l SD of 5 measure-
ments. Values in the same method with different superscript
letters are significantly different (p a 0.05). This figure is
adapted from [124].S.Gorinstein etal. Mol. Nutr. Food Res. 2007, 51, 1365–1381
natural product agree that first of all garlic is an active car-
dioprotective agent. Many recently published reports show
thatgarlicpossesses plasma lipid-loweringand plasma anti-
coagulant and antioxidant properties and improves
impaired endothelial function. However, some investigators
reported that it is still uncertain whether garlic or garlic
preparations can be used as lipid-lowering agents. Why
after many years of scientific studies there are proponents
and opponents of garlic use as lipid-lowering agent? Most
authorssharetheopinionofthebelow-mentionedinvestiga-
tors [70, 125, 126]. According to them, the negative results
obtained in some clinical trials may result from usage of
different garlic preparations, unknown active constituents
and their bioavailability, inadequate randomization, selec-
tion of inappropriate subjects, and short duration of trials.
Therefore, theystate“althoughgarlic appearstoholdprom-
ise in reducing parameters associated with cardiovascular
disease, more in-depth and appropriate studies are
required” [70].
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